[Medical economics in year 2001 as exemplified by Helicobacter pylori].
Oberender
P
P
Universität Bayreuth, Lehrstuhl für Volkswirtschaftslehre, Gesundheitsökonomie, 95440 Bayreuth.
Heissel
A
A
D000900:Anti-Bacterial Agents; D002985:Clinical Protocols; D003362:Cost-Benefit Analysis; D019468:Disease Management; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000191:economics / Q000627:therapeutic use; D004470:Economics, Medical / Q000639:trends*; D005194:Family Practice / Q000191:economics*; D005858:Germany; D016481:Helicobacter Infections / Q000188:drug therapy / Q000191:economics*; D016480:Helicobacter pylori; D006801:Humans; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000191:economics* / Q000592:standards
D000900:Anti-Bacterial Agents